LobbyingAmerican Clinical Laboratory Assn lobbying by quarter
American Clinical Laboratory Assn's latest lobbying report covers Q2 2026, at $890K. The four quarters Q4 2025–Q3 2026 total $2.5M. Its first report covers Q4 2022; the issues it reports most are Health Issues and Medical/Disease Research/Clinical Labs.
American Clinical Laboratory Assn
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $2.5M
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $1.3M | 1 |
| Q1 2023 | $446.3K | 1 |
| Q2 2023 | $633.7K | 1 |
| Q3 2023 | $739.8K | 1 |
| Q4 2023 | $544.5K | 1 |
| Q1 2024 | $375K | 1 |
| Q2 2024 | $575K | 1 |
| Q3 2024 | $425K | 1 |
| Q4 2024 | $510K | 1 |
| Q1 2025 | $580K | 1 |
| Q2 2025 | $510K | 1 |
| Q3 2025 | $610K | 1 |
| Q4 2025 | $930K | 1 |
| Q1 2026 | $660K | 1 |
| Q2 2026 | $890K | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$2.7M · 15 reports
- Medical research and clinical labs$2.7M · 15 reports
- Medicare and Medicaid$2.7M · 15 reports
- Disaster planning and emergencies$764.1K · 5 reports
- Budget and appropriations$627.9K · 4 reports
- Immigration$387.5K · 2 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES15 reports
- SENATE15 reports
- Centers For Medicare and Medicaid Services (CMS)12 reports
- Health & Human Services, Dept of (HHS)10 reports
- Food & Drug Administration (FDA)9 reports
- White House Office6 reports
- Centers For Disease Control & Prevention (CDC)5 reports
- Natl Security Council (NSC)2 reports
Firms it paid
| Firm | ||
|---|---|---|
| In-houseAmerican Clinical Laboratory Assn | $9.7M | 15 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| LAURA STEVENS KENT | Dep. Chief, Appr. Dir., LD, Sr. LA, Rep. Charlie Dent; LA, Rep. Jim Greenwood | Q2 2026 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/17for Q2 | In-house | $890K |
| 04/17for Q1 | In-house | $660K |
| 01/16for Q4 2025 | In-house | $930K |
| 25/10/17for Q2 2025 | In-house | $510K |
| 25/10/17for Q3 2025 | In-house | $610K |
| 25/07/16for Q2 2025 | In-house | $450K |
| 25/04/18for Q1 2025 | In-house | $580K |
| 25/01/15for Q4 2024 | In-house | $510K |
| 24/11/08for Q1 2024 | In-house | $375K |
| 24/11/08for Q2 2024 | In-house | $575K |
| 24/11/08for Q3 2024 | In-house | $425K |
| 24/10/17for Q3 2024 | In-house | $540K |
| 24/07/19for Q2 2024 | In-house | $690K |
| 24/04/19for Q1 2024 | In-house | $490K |
| 24/01/17for Q4 2023 | In-house | $544.5K |
| 23/10/19for Q3 2023 | In-house | $739.8K |
| 23/07/18for Q2 2023 | In-house | $633.7K |
| 23/04/20for Q1 2023 | In-house | $446.3K |
| 23/01/20for Q4 2022 | In-house | $1.3M |